Loading…
Incidence of polyomavirus‐nephropathy in renal allografts: influence of modern immunosuppressive drugs
Background. In recent years an increasing number of cases with polyomavirus (PV)‐nephropathy after renal transplantation were reported from several transplant centres. New, highly potent immunosuppressive drugs like tacrolimus or mycophenolate mofetil were accused as risk factors for this increase....
Saved in:
| Published in: | Nephrology, dialysis, transplantation dialysis, transplantation, 2003-06, Vol.18 (6), p.1190-1196 |
|---|---|
| Main Authors: | , , , , , , |
| Format: | Article |
| Language: | English |
| Subjects: | |
| Citations: | Items that this one cites Items that cite this one |
| Online Access: | Get full text |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| cited_by | cdi_FETCH-LOGICAL-c453t-93d00473feb3b829963efdf0d5ce83315898b8e08412cadd31ce8aba74dce65c3 |
|---|---|
| cites | cdi_FETCH-LOGICAL-c453t-93d00473feb3b829963efdf0d5ce83315898b8e08412cadd31ce8aba74dce65c3 |
| container_end_page | 1196 |
| container_issue | 6 |
| container_start_page | 1190 |
| container_title | Nephrology, dialysis, transplantation |
| container_volume | 18 |
| creator | Mengel, Michael Marwedel, Magali Radermacher, Jörg Eden, Gabriele Schwarz, Anke Haller, Hermann Kreipe, Hans |
| description | Background. In recent years an increasing number of cases with polyomavirus (PV)‐nephropathy after renal transplantation were reported from several transplant centres. New, highly potent immunosuppressive drugs like tacrolimus or mycophenolate mofetil were accused as risk factors for this increase. However, data about the incidence of PV‐nephropathy in correlation to different immunosuppressive therapy concepts are lacking. Methods. All renal transplant biopsies performed at Hannover Medical School between 1999 and 2001 (n=1276) were immunohistochemically screened for the presence of PV‐specific proteins. The results were correlated to the different immunosuppressive therapy protocols and patients with PV‐nephropathy were compared with a matched control group. Results. PV‐nephropathy was found in |
| doi_str_mv | 10.1093/ndt/gfg072 |
| format | article |
| fullrecord | <record><control><sourceid>istex_cross</sourceid><recordid>TN_cdi_crossref_primary_10_1093_ndt_gfg072</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>ark_67375_HXZ_PRTX3BFJ_B</sourcerecordid><originalsourceid>FETCH-LOGICAL-c453t-93d00473feb3b829963efdf0d5ce83315898b8e08412cadd31ce8aba74dce65c3</originalsourceid><addsrcrecordid>eNpFkMtKw0AUhgdRbK1ufADJxo0QO5OZJBN3tlhbKShSobgZJnNpo7kxkxS78xF8Rp_EkVS7OvD_3zkcPgDOEbxGMMHDUjbDlV7BODgAfUQi6AeYhoeg70rkwxAmPXBi7RuEMAni-Bj0UBATikPSB-tZKTKpSqG8Snt1lW-rgm8y09rvz69S1WtT1bxZb72s9Iwqee7xPK9WhuvG3rhQ5-3fclFJZUovK4q2rGxb10ZZm22UJ027sqfgSPPcqrPdHICXyd1iPPXnj_ez8e3cFyTEjZ9gCSGJsVYpTmmQJBFWWmooQ6EoxiikCU2pgpSgQHApMXI5T3lMpFBRKPAAXHV3hamsNUqz2mQFN1uGIPvVxZwu1uly8EUH121aKLlHd34ccLkDuBU814Y7XXbPkQRT5H4cAL_jMtuoj_-em3cWxTgO2XT5yp6eF0s8mjywEf4BvBqHfQ</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>Incidence of polyomavirus‐nephropathy in renal allografts: influence of modern immunosuppressive drugs</title><source>Oxford Journals Online</source><creator>Mengel, Michael ; Marwedel, Magali ; Radermacher, Jörg ; Eden, Gabriele ; Schwarz, Anke ; Haller, Hermann ; Kreipe, Hans</creator><creatorcontrib>Mengel, Michael ; Marwedel, Magali ; Radermacher, Jörg ; Eden, Gabriele ; Schwarz, Anke ; Haller, Hermann ; Kreipe, Hans</creatorcontrib><description>Background. In recent years an increasing number of cases with polyomavirus (PV)‐nephropathy after renal transplantation were reported from several transplant centres. New, highly potent immunosuppressive drugs like tacrolimus or mycophenolate mofetil were accused as risk factors for this increase. However, data about the incidence of PV‐nephropathy in correlation to different immunosuppressive therapy concepts are lacking. Methods. All renal transplant biopsies performed at Hannover Medical School between 1999 and 2001 (n=1276) were immunohistochemically screened for the presence of PV‐specific proteins. The results were correlated to the different immunosuppressive therapy protocols and patients with PV‐nephropathy were compared with a matched control group. Results. PV‐nephropathy was found in <1% of all investigated allograft biopsies (11/1276) and in ∼1% of all patients (7/638), respectively. All patients being immunohistochemically positive for PV‐specific proteins also showed the typical morphological changes of PV‐nephropathy. Four out of seven patients with PV‐nephropathy were under triple immunosuppression comprising tacrolimus and mycophenolate mofetil. Under this immunosuppressive therapy protocol an eight times higher incidence and a 13 times higher risk (multivariate odds ratio 12.7) of PV‐nephropathy was observed in our patients compared with the control group. Conclusions. PV‐nephropathy is a rare but serious complication after renal transplantation. A small group of patients under intensive immunosuppression comprising tacrolimus in combination with mycophenolate mofetil has a significantly increased risk of acquiring this deleterious complication.</description><identifier>ISSN: 0931-0509</identifier><identifier>EISSN: 1460-2385</identifier><identifier>DOI: 10.1093/ndt/gfg072</identifier><identifier>PMID: 12748354</identifier><identifier>CODEN: NDTREA</identifier><language>eng</language><publisher>Oxford: Oxford University Press</publisher><subject>Adolescent ; Adult ; Aged ; Anesthesia. Intensive care medicine. Transfusions. Cell therapy and gene therapy ; Biological and medical sciences ; Child ; Child, Preschool ; Drug Therapy, Combination ; Emergency and intensive care: renal failure. Dialysis management ; Female ; Graft Rejection - pathology ; Graft Rejection - prevention & control ; Graft Rejection - virology ; Graft Survival ; Humans ; Immunosuppressive Agents - adverse effects ; Immunosuppressive Agents - therapeutic use ; Intensive care medicine ; Kidney Failure, Chronic - surgery ; Kidney Transplantation ; Male ; Medical sciences ; Middle Aged ; Mycophenolic Acid - adverse effects ; Mycophenolic Acid - analogs & derivatives ; Mycophenolic Acid - therapeutic use ; Polyomavirus ; Polyomavirus Infections - etiology ; Prospective Studies ; renal transplantation ; Risk Factors ; Tacrolimus - adverse effects ; Tacrolimus - therapeutic use ; Tumor Virus Infections - etiology</subject><ispartof>Nephrology, dialysis, transplantation, 2003-06, Vol.18 (6), p.1190-1196</ispartof><rights>2004 INIST-CNRS</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c453t-93d00473feb3b829963efdf0d5ce83315898b8e08412cadd31ce8aba74dce65c3</citedby><cites>FETCH-LOGICAL-c453t-93d00473feb3b829963efdf0d5ce83315898b8e08412cadd31ce8aba74dce65c3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27923,27924</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=14938196$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/12748354$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Mengel, Michael</creatorcontrib><creatorcontrib>Marwedel, Magali</creatorcontrib><creatorcontrib>Radermacher, Jörg</creatorcontrib><creatorcontrib>Eden, Gabriele</creatorcontrib><creatorcontrib>Schwarz, Anke</creatorcontrib><creatorcontrib>Haller, Hermann</creatorcontrib><creatorcontrib>Kreipe, Hans</creatorcontrib><title>Incidence of polyomavirus‐nephropathy in renal allografts: influence of modern immunosuppressive drugs</title><title>Nephrology, dialysis, transplantation</title><addtitle>Nephrol. Dial. Transplant</addtitle><description>Background. In recent years an increasing number of cases with polyomavirus (PV)‐nephropathy after renal transplantation were reported from several transplant centres. New, highly potent immunosuppressive drugs like tacrolimus or mycophenolate mofetil were accused as risk factors for this increase. However, data about the incidence of PV‐nephropathy in correlation to different immunosuppressive therapy concepts are lacking. Methods. All renal transplant biopsies performed at Hannover Medical School between 1999 and 2001 (n=1276) were immunohistochemically screened for the presence of PV‐specific proteins. The results were correlated to the different immunosuppressive therapy protocols and patients with PV‐nephropathy were compared with a matched control group. Results. PV‐nephropathy was found in <1% of all investigated allograft biopsies (11/1276) and in ∼1% of all patients (7/638), respectively. All patients being immunohistochemically positive for PV‐specific proteins also showed the typical morphological changes of PV‐nephropathy. Four out of seven patients with PV‐nephropathy were under triple immunosuppression comprising tacrolimus and mycophenolate mofetil. Under this immunosuppressive therapy protocol an eight times higher incidence and a 13 times higher risk (multivariate odds ratio 12.7) of PV‐nephropathy was observed in our patients compared with the control group. Conclusions. PV‐nephropathy is a rare but serious complication after renal transplantation. A small group of patients under intensive immunosuppression comprising tacrolimus in combination with mycophenolate mofetil has a significantly increased risk of acquiring this deleterious complication.</description><subject>Adolescent</subject><subject>Adult</subject><subject>Aged</subject><subject>Anesthesia. Intensive care medicine. Transfusions. Cell therapy and gene therapy</subject><subject>Biological and medical sciences</subject><subject>Child</subject><subject>Child, Preschool</subject><subject>Drug Therapy, Combination</subject><subject>Emergency and intensive care: renal failure. Dialysis management</subject><subject>Female</subject><subject>Graft Rejection - pathology</subject><subject>Graft Rejection - prevention & control</subject><subject>Graft Rejection - virology</subject><subject>Graft Survival</subject><subject>Humans</subject><subject>Immunosuppressive Agents - adverse effects</subject><subject>Immunosuppressive Agents - therapeutic use</subject><subject>Intensive care medicine</subject><subject>Kidney Failure, Chronic - surgery</subject><subject>Kidney Transplantation</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Middle Aged</subject><subject>Mycophenolic Acid - adverse effects</subject><subject>Mycophenolic Acid - analogs & derivatives</subject><subject>Mycophenolic Acid - therapeutic use</subject><subject>Polyomavirus</subject><subject>Polyomavirus Infections - etiology</subject><subject>Prospective Studies</subject><subject>renal transplantation</subject><subject>Risk Factors</subject><subject>Tacrolimus - adverse effects</subject><subject>Tacrolimus - therapeutic use</subject><subject>Tumor Virus Infections - etiology</subject><issn>0931-0509</issn><issn>1460-2385</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2003</creationdate><recordtype>article</recordtype><recordid>eNpFkMtKw0AUhgdRbK1ufADJxo0QO5OZJBN3tlhbKShSobgZJnNpo7kxkxS78xF8Rp_EkVS7OvD_3zkcPgDOEbxGMMHDUjbDlV7BODgAfUQi6AeYhoeg70rkwxAmPXBi7RuEMAni-Bj0UBATikPSB-tZKTKpSqG8Snt1lW-rgm8y09rvz69S1WtT1bxZb72s9Iwqee7xPK9WhuvG3rhQ5-3fclFJZUovK4q2rGxb10ZZm22UJ027sqfgSPPcqrPdHICXyd1iPPXnj_ez8e3cFyTEjZ9gCSGJsVYpTmmQJBFWWmooQ6EoxiikCU2pgpSgQHApMXI5T3lMpFBRKPAAXHV3hamsNUqz2mQFN1uGIPvVxZwu1uly8EUH121aKLlHd34ccLkDuBU814Y7XXbPkQRT5H4cAL_jMtuoj_-em3cWxTgO2XT5yp6eF0s8mjywEf4BvBqHfQ</recordid><startdate>20030601</startdate><enddate>20030601</enddate><creator>Mengel, Michael</creator><creator>Marwedel, Magali</creator><creator>Radermacher, Jörg</creator><creator>Eden, Gabriele</creator><creator>Schwarz, Anke</creator><creator>Haller, Hermann</creator><creator>Kreipe, Hans</creator><general>Oxford University Press</general><scope>BSCLL</scope><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope></search><sort><creationdate>20030601</creationdate><title>Incidence of polyomavirus‐nephropathy in renal allografts: influence of modern immunosuppressive drugs</title><author>Mengel, Michael ; Marwedel, Magali ; Radermacher, Jörg ; Eden, Gabriele ; Schwarz, Anke ; Haller, Hermann ; Kreipe, Hans</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c453t-93d00473feb3b829963efdf0d5ce83315898b8e08412cadd31ce8aba74dce65c3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2003</creationdate><topic>Adolescent</topic><topic>Adult</topic><topic>Aged</topic><topic>Anesthesia. Intensive care medicine. Transfusions. Cell therapy and gene therapy</topic><topic>Biological and medical sciences</topic><topic>Child</topic><topic>Child, Preschool</topic><topic>Drug Therapy, Combination</topic><topic>Emergency and intensive care: renal failure. Dialysis management</topic><topic>Female</topic><topic>Graft Rejection - pathology</topic><topic>Graft Rejection - prevention & control</topic><topic>Graft Rejection - virology</topic><topic>Graft Survival</topic><topic>Humans</topic><topic>Immunosuppressive Agents - adverse effects</topic><topic>Immunosuppressive Agents - therapeutic use</topic><topic>Intensive care medicine</topic><topic>Kidney Failure, Chronic - surgery</topic><topic>Kidney Transplantation</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Middle Aged</topic><topic>Mycophenolic Acid - adverse effects</topic><topic>Mycophenolic Acid - analogs & derivatives</topic><topic>Mycophenolic Acid - therapeutic use</topic><topic>Polyomavirus</topic><topic>Polyomavirus Infections - etiology</topic><topic>Prospective Studies</topic><topic>renal transplantation</topic><topic>Risk Factors</topic><topic>Tacrolimus - adverse effects</topic><topic>Tacrolimus - therapeutic use</topic><topic>Tumor Virus Infections - etiology</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Mengel, Michael</creatorcontrib><creatorcontrib>Marwedel, Magali</creatorcontrib><creatorcontrib>Radermacher, Jörg</creatorcontrib><creatorcontrib>Eden, Gabriele</creatorcontrib><creatorcontrib>Schwarz, Anke</creatorcontrib><creatorcontrib>Haller, Hermann</creatorcontrib><creatorcontrib>Kreipe, Hans</creatorcontrib><collection>Istex</collection><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><jtitle>Nephrology, dialysis, transplantation</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Mengel, Michael</au><au>Marwedel, Magali</au><au>Radermacher, Jörg</au><au>Eden, Gabriele</au><au>Schwarz, Anke</au><au>Haller, Hermann</au><au>Kreipe, Hans</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Incidence of polyomavirus‐nephropathy in renal allografts: influence of modern immunosuppressive drugs</atitle><jtitle>Nephrology, dialysis, transplantation</jtitle><addtitle>Nephrol. Dial. Transplant</addtitle><date>2003-06-01</date><risdate>2003</risdate><volume>18</volume><issue>6</issue><spage>1190</spage><epage>1196</epage><pages>1190-1196</pages><issn>0931-0509</issn><eissn>1460-2385</eissn><coden>NDTREA</coden><abstract>Background. In recent years an increasing number of cases with polyomavirus (PV)‐nephropathy after renal transplantation were reported from several transplant centres. New, highly potent immunosuppressive drugs like tacrolimus or mycophenolate mofetil were accused as risk factors for this increase. However, data about the incidence of PV‐nephropathy in correlation to different immunosuppressive therapy concepts are lacking. Methods. All renal transplant biopsies performed at Hannover Medical School between 1999 and 2001 (n=1276) were immunohistochemically screened for the presence of PV‐specific proteins. The results were correlated to the different immunosuppressive therapy protocols and patients with PV‐nephropathy were compared with a matched control group. Results. PV‐nephropathy was found in <1% of all investigated allograft biopsies (11/1276) and in ∼1% of all patients (7/638), respectively. All patients being immunohistochemically positive for PV‐specific proteins also showed the typical morphological changes of PV‐nephropathy. Four out of seven patients with PV‐nephropathy were under triple immunosuppression comprising tacrolimus and mycophenolate mofetil. Under this immunosuppressive therapy protocol an eight times higher incidence and a 13 times higher risk (multivariate odds ratio 12.7) of PV‐nephropathy was observed in our patients compared with the control group. Conclusions. PV‐nephropathy is a rare but serious complication after renal transplantation. A small group of patients under intensive immunosuppression comprising tacrolimus in combination with mycophenolate mofetil has a significantly increased risk of acquiring this deleterious complication.</abstract><cop>Oxford</cop><pub>Oxford University Press</pub><pmid>12748354</pmid><doi>10.1093/ndt/gfg072</doi><tpages>7</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0931-0509 |
| ispartof | Nephrology, dialysis, transplantation, 2003-06, Vol.18 (6), p.1190-1196 |
| issn | 0931-0509 1460-2385 |
| language | eng |
| recordid | cdi_crossref_primary_10_1093_ndt_gfg072 |
| source | Oxford Journals Online |
| subjects | Adolescent Adult Aged Anesthesia. Intensive care medicine. Transfusions. Cell therapy and gene therapy Biological and medical sciences Child Child, Preschool Drug Therapy, Combination Emergency and intensive care: renal failure. Dialysis management Female Graft Rejection - pathology Graft Rejection - prevention & control Graft Rejection - virology Graft Survival Humans Immunosuppressive Agents - adverse effects Immunosuppressive Agents - therapeutic use Intensive care medicine Kidney Failure, Chronic - surgery Kidney Transplantation Male Medical sciences Middle Aged Mycophenolic Acid - adverse effects Mycophenolic Acid - analogs & derivatives Mycophenolic Acid - therapeutic use Polyomavirus Polyomavirus Infections - etiology Prospective Studies renal transplantation Risk Factors Tacrolimus - adverse effects Tacrolimus - therapeutic use Tumor Virus Infections - etiology |
| title | Incidence of polyomavirus‐nephropathy in renal allografts: influence of modern immunosuppressive drugs |
| url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-10T22%3A26%3A03IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-istex_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Incidence%20of%20polyomavirus%E2%80%90nephropathy%20in%20renal%20allografts:%20influence%20of%20modern%20immunosuppressive%20drugs&rft.jtitle=Nephrology,%20dialysis,%20transplantation&rft.au=Mengel,%20Michael&rft.date=2003-06-01&rft.volume=18&rft.issue=6&rft.spage=1190&rft.epage=1196&rft.pages=1190-1196&rft.issn=0931-0509&rft.eissn=1460-2385&rft.coden=NDTREA&rft_id=info:doi/10.1093/ndt/gfg072&rft_dat=%3Cistex_cross%3Eark_67375_HXZ_PRTX3BFJ_B%3C/istex_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c453t-93d00473feb3b829963efdf0d5ce83315898b8e08412cadd31ce8aba74dce65c3%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_id=info:pmid/12748354&rfr_iscdi=true |